...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of oral and maxillofacial surgery >Intra-arterial chemoradiation therapy with weekly low-dose cisplatin for squamous cell carcinoma of the maxillary sinus
【24h】

Intra-arterial chemoradiation therapy with weekly low-dose cisplatin for squamous cell carcinoma of the maxillary sinus

机译：每周小剂量顺铂进行动脉内化学放射治疗上颌窦鳞状细胞癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A new intra-arterial chemoraliation regimen that involves infusing low-dose cisplatin in combination with definitive irradiation was used in 36 patients diagnosed with squamous cell carcinoma of the maxillary sinus. The safety and therapeutic efficacy of this regimen were reviewed retrospectively. An intra-arterial catheter was inserted in a retrograde manner into the target artery via the superficial temporal artery or occipital artery. Intra-arterial infusion was performed using cisplatin at a dose of 20-50 mg/m(2) per week for 6-8 weeks. At the same time, sodium thiosulphate was infused as a neutralizing agent. Irradiation was performed at 60 Gy in 30 fractions. All 36 patients completed treatment. Grade 3 adverse events occurred in only seven patients (19.4%) and no grade 4 events were noted. As a primary therapy, the complete response rate was 83.3%, the partial response rate was 16.7%, and the overall response rate was 100%. The 2-year local control rate was 63.0%, and the 2-year overall survival rate was 75.5%. The 2-year preservation rate of the hard palate was 97.1%, that of the eyeball was 97.2%, and that of visual function was 94.4%. This treatment regimen can contribute to improving the quality of life of patients without reducing the curability of the therapy.
机译：在36例被诊断为上颌窦鳞状细胞癌的患者中，采用了一种新的动脉内化学化方案，该方案涉及注入低剂量顺铂和确定性放疗。回顾性研究该方案的安全性和疗效。动脉内导管通过颞浅动脉或枕动脉逆行插入目标动脉。使用顺铂以每周20-50 mg / m（2）的剂量进行动脉内输注，持续6-8周。同时，注入硫代硫酸钠作为中和剂。以60 Gy分30次照射。全部36例患者均已完成治疗。仅7名患者（19.4％）发生了3级不良事件，未发现4级不良事件。作为主要疗法，完全缓解率为83.3％，部分缓解率为16.7％，总缓解率为100％。 2年局部控制率为63.0％，2年总生存率为75.5％。硬pa的2年保存率是97.1％，眼球的2年保存率是97.2％，视觉功能的2年保存率是94.4％。这种治疗方案可有助于改善患者的生活质量，而不会降低治疗的可治愈性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号